MK-8242 Is Active in Patients with p53 Wild-Type Advanced Solid Tumors [Clinical Trials]

The MDM2 inhibitor MK-8242 is tolerable in patients with liposarcoma and other advanced solid tumors.

from Cancer via ola Kala on Inoreader http://ift.tt/2plQGu4
via IFTTT